Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Distler, P. Holt (1997)
Are right- and left-sided colon neoplasms distinct tumors?Digestive diseases, 15 4-5
M. Bostick, Jong Kim, P. Estève, Amander Clark, S. Pradhan, S. Jacobsen (2007)
UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian CellsScience, 317
C. Karapetis, S. Khambata-Ford, D. Jonker, C. O'Callaghan, D. Tu, N. Tebbutt, R. Simes, H. Chalchal, J. Shapiro, S. Robitaille, T. Price, L. Shepherd, H. Au, C. Langer, M. Moore, J. Zalcberg (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.The New England journal of medicine, 359 17
T. Crnogorac-Jurcevic, R. Gangeswaran, V. Bhakta, G. Capurso, S. Lattimore, M. Akada, M. Sunamura, W. Prime, F. Campbell, T. Brentnall, Eithne Costello, J. Neoptolemos, N. Lemoine (2005)
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.Gastroenterology, 129 5
K. Birkenkamp-Demtröder, S. Olesen, F. Sørensen, Søren Laurberg, P. Laiho, L. Aaltonen, T. Ørntoft (2005)
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoidGut, 54
E. Kapiteijn, G. Liefers, L. Los, E. Kranenbarg, J. Hermans, R. Tollenaar, Y. Moriya, C. Velde, J. Krieken (2001)
Mechanisms of oncogenesis in colon versus rectal cancerThe Journal of Pathology, 195
P. Frič, V. Sovová, E. Šloncová, Z. Lojda, A. Jirásek, J. Cermak (2000)
Different expression of some molecular markers in sporadic cancer of the left and right colon.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation, 9 4
R. Hopfner, M. Mousli, J. Jeltsch, Angélique Voulgaris, Yves Lutz, Cristi Marin, J. Bellocq, Pierre Oudet, Christian Bronner (2000)
ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.Cancer research, 60 1
M. Mousli, R. Hopfner, A. Abbady, D. Monté, M. Jeanblanc, P. Oudet, B. Louis, C. Bronner (2003)
ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cellsBritish Journal of Cancer, 89
A. Abbady, C. Bronner, Kawtar Bathami, C. Muller, M. Jeanblanc, E. Mathieu, J. Klein, E. Candolfi, M. Mousli (2005)
TCR pathway involves ICBP90 gene down-regulation via E2F binding sites.Biochemical pharmacology, 70 4
S. Oba-Shinjo, M. Bengtson, S. Winnischofer, C. Colín, C. Vedoy, Z. Mendonça, S. Marie, M. Sogayar (2005)
Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference analysis.Brain research. Molecular brain research, 140 1-2
Marie-Aline Trotzier, C. Bronner, Kawtar Bathami, E. Mathieu, A. Abbady, M. Jeanblanc, C. Muller, C. Rochette-Egly, M. Mousli (2004)
Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase IIalpha expression.Biochemical and biophysical research communications, 319 2
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, J. Cassidy (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
M. Unoki, Julie Brunet, M. Mousli (2009)
Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis.Biochemical pharmacology, 78 10
Daniela Meilinger, K. Fellinger, Sebastian Bultmann, U. Rothbauer, I. Bonapace, W. Klinkert, Fabio Spada, H. Leonhardt (2009)
Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cellsEMBO Reports, 10
M. Unoki, Toshihiko Nishidate, Yusuke Nakamura (2004)
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domainOncogene, 23
Jong Kim, P. Estève, S. Jacobsen, S. Pradhan (2008)
UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cellsNucleic Acids Research, 37
Y. Arima, T. Hirota, C. Bronner, M. Mousli, T. Fujiwara, S. Niwa, H. Ishikawa, H. Saya (2004)
Down‐regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1‐dependent DNA‐damage checkpoint signals contributes to cell cycle arrest at G1/S transitionGenes to Cells, 9
W. Jin, Li Chen, Ying Chen, Siguang Xu, G. Di, W. Yin, Jiong Wu, Z. Shao (2010)
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancerBreast Cancer Research and Treatment, 123
K. Arita, M. Ariyoshi, H. Tochio, Yusuke Nakamura, M. Shirakawa (2008)
Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanismNature, 455
M. Lorenzato, S. Caudroy, C. Bronner, G. Evrard, Maryline Simon, A. Durlach, P. Birembaut, C. Clavel (2005)
Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?Human pathology, 36 10
J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocáková, P. Ruff, M. Błasińska-Morawiec, M. Šmakal, J. Canon, M. Rother, K. Oliner, M. Wolf, J. Gansert (2010)
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 31
M. Unoki, J. Kelly, D. Neal, B. Ponder, Y. Nakamura, Ryuji Hamamoto (2009)
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancerBritish Journal of Cancer, 101
C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio, F. Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh, A. Loos, A. Zubel, P. Koralewski (2009)
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
H. Elsaleh, D. Joseph, F. Grieu, N. Zeps, N. Spry, B. Iacopetta (2000)
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancerThe Lancet, 355
H. Hashimoto, J. Horton, Xing Zhang, M. Bostick, S. Jacobsen, Xiaodong Cheng (2008)
The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helixNature, 455
G. Avvakumov, J. Walker, S. Xue, Yanjun Li, Shili Duan, C. Bronner, C. Arrowsmith, S. Dhe-Paganon (2008)
Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1Nature, 455
J. Sharif, M. Muto, S. Takebayashi, I. Suetake, A. Iwamatsu, T. Endo, J. Shinga, Y. Mizutani-Koseki, Tetsuro Toyoda, K. Okamura, S. Tajima, K. Mitsuya, M. Okano, H. Koseki (2007)
The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNANature, 450
M. Unoki, Y. Daigo, J. Koinuma, E. Tsuchiya, Ryuji Hamamoto, Y. Nakamura (2010)
UHRF1 is a novel diagnostic marker of lung cancerBritish Journal of Cancer, 103
Ubiquitin-like with PHD and ring-finger domain 1 (UHRF1) binds to methylated promoters of a number of tumor-suppressor genes, including p16INK4A and p14ARF, by forming complexes with DNA methyltransferases and HDAC1, resulting in the induction of carcinogenesis. Altered UHRF1 expression has been demonstrated in various types of cancers. Previous reports indicate that UHRF1 expression is regulated by E2F-1 expression. We investigated UHRF1 expression using immunohistochemical staining in 231 colorectal cancer and 40 adenoma specimens, analyzed the relationship between UHRF1 expression and clinicopathological findings and the association between UHRF1 and E2F-1 expression. To better understand the biological function of UHRF1 in colorectal cancer, knockdown of UHRF1 expression was performed using siRNA methods. High UHRF1 expression was observed in 152 of 231 (65.8%) colorectal cancer patients, and was detected in 35 of 40 adenoma specimens samples (87.5%). UHRF1 staining was detected in the nucleus of cancer cells, while it was not detected in colonic normal mucosa. High UHRF1 expression was significantly observed in right compared with left hemicolon cancer (p=0.008). Moreover, high UHRF1 expression tended to be associated with depth of invasion (p=0.051). UHRF1 expression was significantly associated with E2F-1 expression (p<0.0001). Knockdown of UHRF1 expression suppressed cellular growth in colon cancer cell lines, HCT116 and SW620. In conclusion, we demonstrated that UHRF1 expression was upregulated in approximately two-thirds of colorectal cancer specimens and was particularly expressed in right compared with left hemicolon cancer. Moreover, knockdown of UHRF1 expression induced growth inhibition in colon cancer cell lines. UHRF1 may be involved in cellular proliferation and molecular pathogenesis of colorectal cancer in the right hemicolon.
Oncology Reports – Spandidos Publications
Published: Dec 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.